Survodutide, also known by its development code BI 456906, is a synthetic 29-amino-acid peptide engineered to act as a dual agonist at both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor (GCGR). It is studied as a research tool for probing combined incretin and glucagon receptor signalling, conceptually modelled on the endogenous gut peptide oxyntomodulin, which weakly activates both receptors naturally. Survodutide is of particular research interest because its glucagon receptor component is reported to act through a mechanism, increased energy expenditure, that is distinct from the appetite-suppressing GLP-1 receptor pathway shared by single-target incretin compounds. This article reviews its structure, dual-receptor mechanism, key published studies, research applications and the handling requirements relevant to a laboratory setting.
What is survodutide?
Survodutide is a 29-residue synthetic peptide built on the native human glucagon sequence backbone, with amino acid substitutions introduced at several positions, commonly described in the literature as positions 18, 20 and 23, which confer agonist activity at the GLP-1 receptor in addition to the glucagon receptor activity inherent to the glucagon-derived sequence. As with other long-acting peptide research compounds, survodutide incorporates a fatty acid modification intended to promote albumin binding and extend plasma half-life, supporting the once-weekly dosing interval used in its clinical research programme. Its design is explicitly described in the literature as conceptually based on oxyntomodulin, a naturally occurring gut peptide that weakly activates both the GLP-1 and glucagon receptors and has itself been studied for effects on energy balance.
Survodutide was discovered and developed through a collaboration between Zealand Pharma and Boehringer Ingelheim. Its discovery and preclinical pharmacological characterisation, including receptor potency profiling and efficacy testing in diet-induced obese mice, was reported by Zimmermann and colleagues in Molecular Metabolism in 2022 (Zimmermann et al., 2022, PMC).
Mechanism of action
Survodutide engages two distinct class B G protein-coupled receptors. The GLP-1 receptor (GLP-1R), expressed on pancreatic beta cells and in the central nervous system, couples to Gs proteins and activates adenylate cyclase, raising cyclic AMP and driving glucose-dependent insulin secretion, delayed gastric emptying and central appetite suppression, the same mechanism shared by selective GLP-1 receptor agonists. Published pharmacology describes survodutide’s potency at the GLP-1 receptor as somewhat lower than that of native GLP-1 itself, consistent with a deliberately balanced, rather than GLP-1-dominant, dual-agonist design.
The glucagon receptor component is what distinguishes survodutide mechanistically from single-target GLP-1 receptor agonists. Glucagon receptor activation in the liver and adipose tissue is reported to increase energy expenditure and influence hepatic lipid metabolism, including fatty acid oxidation, effects proposed to complement the appetite-suppressing, intake-reducing action of GLP-1 receptor agonism. The foundational 2022 preclinical characterisation reported that survodutide’s glucagon receptor potency was weaker, relative to native glucagon, than its GLP-1 receptor potency relative to native GLP-1, consistent with a design intended to achieve meaningful glucagon receptor engagement without producing the hyperglycaemic effect associated with strong, unopposed glucagon receptor activation.
Because these two receptor pathways act through complementary rather than overlapping mechanisms, reduced energy intake via GLP-1 receptor agonism and increased energy expenditure via glucagon receptor agonism, survodutide is studied as a model compound for examining whether combining these mechanisms in a single molecule produces effects exceeding those of GLP-1 receptor agonism alone, a question examined directly in the preclinical and clinical research described below.
What the research shows
The foundational preclinical characterisation of survodutide (BI 456906) was reported by Zimmermann and colleagues in Molecular Metabolism in 2022. The study reported in vitro functional receptor potency at both GLP-1R and GCGR, and compared survodutide’s effects on body weight against maximally effective doses of the selective GLP-1 receptor agonist semaglutide in diet-induced obese mice. The investigators reported that survodutide produced greater body weight reductions than semaglutide in this model, attributed the additional effect to increased energy expenditure consistent with glucagon receptor engagement, and reported corresponding biomarker changes, including elevated FGF-21 and reductions in cholesterol and triglyceride measures, consistent with the proposed dual mechanism (Zimmermann et al., 2022, PMC).
Building on this preclinical foundation, le Roux and colleagues reported a phase 2, randomised, double-blind, placebo-controlled, dose-finding clinical trial in the Lancet Diabetes & Endocrinology in 2024. Conducted across 43 centres in 12 countries in adults with a body mass index of 27 kg/m² or greater without diabetes, the 46-week trial examined several survodutide doses against placebo, with body weight change as a key endpoint. The investigators reported dose-dependent reductions in body weight, with the highest dose tested producing substantially greater weight loss than placebo, within the specific clinical trial population studied (le Roux et al., 2024, PubMed).
A separate randomised clinical trial, reported by Blüher and colleagues, examined survodutide specifically in people with type 2 diabetes, assessing dose-response effects on glycated haemoglobin and body weight compared with both placebo and open-label semaglutide. The study reported that survodutide reduced glycated haemoglobin and produced dose-dependent body weight reductions over 16 weeks, with higher survodutide doses producing numerically greater body weight reduction than the semaglutide comparator arm within the trial population studied (Blüher et al., PMID 38095657).
Further clinical trial work, including phase 3 trials examining survodutide in obesity and in metabolic dysfunction-associated steatotic liver disease, is ongoing or has been reported more recently, reflecting an active and expanding published literature on this compound. Because this clinical trial programme is extensive and still developing, readers wanting the most current primary data should consult the individual trial publications rather than rely on a single summarised study here.
Research applications
In the laboratory, survodutide is used mainly as a pharmacological tool for studying combined GLP-1 and glucagon receptor signalling, drawing on the receptor potency profiling and diet-induced obesity model methodology established in the foundational 2022 preclinical characterisation. Cell-based receptor pharmacology, using cell lines engineered to express GLP-1R, GCGR, or both, is used to characterise survodutide’s binding affinity and signalling efficacy at each receptor, in comparison with selective single-receptor agonists and with the endogenous dual agonist oxyntomodulin on which its design is conceptually based.
Rodent models of diet-induced obesity are a core application, used to study the combined effects of dual GLP-1/glucagon receptor agonism on body weight, food intake and energy expenditure, frequently benchmarked directly against selective GLP-1 receptor agonists such as semaglutide to isolate the additional contribution of glucagon receptor engagement, following the comparative design used in the original preclinical study.
Because the glucagon receptor component is reported to influence hepatic lipid metabolism, survodutide is also used in research examining effects on markers relevant to liver fat and metabolic dysfunction, an area reflected in its more recent clinical trial programme, and in energy expenditure and biomarker research examining FGF-21 and related metabolic signalling pathways identified in the foundational mouse studies.
Purity, storage and handling
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing Survodutide should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and those comparing suppliers should look for the same documentation from any best peptides supplier UK they consider.
Reversed-phase HPLC separates the intact 29-residue peptide from truncated or deletion sequences and residual synthesis by-products, and research-grade material is commonly specified at 98% purity or above. Mass spectrometry alongside HPLC confirms identity against the expected mass for the full-length, fatty-acid-conjugated peptide. Given the molecule’s fatty acid modification, confirming correctly conjugated, full-length peptide, rather than an unconjugated or partially degraded form, is particularly relevant to reproducible receptor-binding and in vivo data. A batch-specific certificate of analysis, rather than a generic product datasheet, is what links a physical vial to those results and allows unexpected experimental data to be traced back to a defined lot.
Lyophilised survodutide should be kept sealed at -20°C for long-term storage, protected from moisture and light, and brought to room temperature before opening so that condensation does not enter the vial. Once reconstituted in sterile water or an appropriate buffer, the peptide should be divided into single-use aliquots, held at 2–8°C only for short working periods, and otherwise kept frozen, since repeated freeze–thaw cycles risk degrading the peptide. Aromatic residues within the sequence are susceptible to photo-oxidation, so amber vials or foil-wrapped storage are sensible precautions during handling. Published reconstituted-stability data specific to research-grade survodutide are limited in the open literature, so laboratories should validate their own working window empirically, for example by comparing HPLC profiles of fresh and aged aliquots.
Frequently asked questions
What is survodutide used for in research?
It is used mainly as a pharmacological tool for studying combined GLP-1 and glucagon receptor signalling, and for examining how combining appetite-suppressing and energy-expenditure-increasing mechanisms in one molecule affects body weight and metabolic parameters in cell and animal models. It is not evaluated here as a treatment, and this article makes no claims about use in humans.
How does survodutide differ from GLP-1-only compounds like semaglutide?
Semaglutide acts selectively at the GLP-1 receptor, reducing appetite and food intake. Survodutide additionally activates the glucagon receptor, which published preclinical research has linked to increased energy expenditure and effects on hepatic lipid metabolism, a mechanism proposed to add to, rather than duplicate, GLP-1 receptor agonism alone.
How does survodutide differ from tirz2?
Tirzepatide is a dual agonist at the GLP-1 and GIP receptors, whereas survodutide is a dual agonist at the GLP-1 and glucagon receptors, making them mechanistically distinct classes of dual incretin-related compounds despite some superficial similarity as once-weekly injectable peptides under clinical investigation for similar research areas.
Is survodutide an approved medicine?
No. Survodutide remains an investigational compound in clinical trials, including phase 3 studies, and is not an approved medicine in the UK or elsewhere at the time of writing. This article concerns laboratory research material only, which is not equivalent to a licensed pharmaceutical product, and makes no claims about administration to humans or animals.
The survodutide discussed in this article is supplied for in-vitro and in-vivo laboratory research only. It is not intended for human or veterinary use, and nothing in this article should be read as guidance on administration to people or animals.
